Integra Plans to Acquire J&J Neurosurgery Business for $1b in cash

Medical Devices Directory Forums Business Partnering Integra Plans to Acquire J&J Neurosurgery Business for $1b in cash

This topic contains 0 replies, has 1 voice, and was last updated by  Global Medtech 1 year, 2 months ago.

Viewing 1 post (of 1 total)
  • Author
  • #3291

    Global Medtech

    Integra LifeSciences Holdings Corporation announced that it has made a binding offer to acquire the Johnson & Johnson Codman Neurosurgery business for a price of $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro-critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a leading global provider of neurosurgical products.  
    “This proposed transformational acquisition of Codman Neurosurgery creates compelling value for our shareholders, employees and patients,” said Peter Arduini, Integra’s president and chief executive officer. “Its innovative portfolio and global reach will enable us to enhance our position in the neurosurgery market, while also building a global infrastructure that will benefit Integra as a whole. We look forward to welcoming the more than 600 Codman Neurosurgery employees to the Integra team.”
    Codman Neurosurgery’s existing portfolio and new product pipeline in advanced hydrocephalus, neuro-critical care and electrosurgery complement Integra’s leading products and pipeline in tissue ablation, dural repair and cranial stabilization. Together, this comprehensive portfolio will offer customers around the world complete solutions for neurosurgery and the scale to invest and bring new technologies to patients worldwide.  The acquired products generated approximately $370 million in revenue during 2016 with an EBITDA margin of about 31% (unaudited). 
    Codman Neurosurgery is a part of Depuy Synthes Companies of Johnson & Johnson.

    Source: Integra LifeSciences

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.